Ivana Magovcevic-Liebisch
CIK: 0001279281
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Oct 2, 2026QTRX
Quanterix Corp
Exercise(M)Direct4.2K shares- - Jun 17, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)Direct9.4K shares- - Jan 2, 2026QTRX
Quanterix Corp
Award(A)Direct23.4K shares- - Aug 5, 2025VIGL
Vigil Neuroscience, Inc.
Disposition(D)Direct222.7K shares- - Jun 13, 2025ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - Mar 3, 2025VIGL
Vigil Neuroscience, Inc.
Award(A)DirectStock Option Award (Right to Buy)
485K shares- - Jan 2, 2025QTRX
Quanterix Corp
Award(A)Direct7.4K shares- - Dec 19, 2024VIGL
Vigil Neuroscience, Inc.
Purchase(P)Direct5K shares at avg. $1.68$8K - Dec 18, 2024VIGL
Vigil Neuroscience, Inc.
Purchase(P)Direct5K shares at avg. $1.67$8K - Dec 5, 2024VIGL
Vigil Neuroscience, Inc.
Purchase(P)Direct5K shares at avg. $2.34$12K - Oct 2, 2024QTRX
Quanterix Corp
Award(A)Direct12.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 2, 2026 |  QTRX Quanterix Corp | Exercise(M) | 4,224 | - | $0 | Direct |
| Jun 17, 2026 |  ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc. | Award(A) | 9,366 | - | $0 | Direct |
| Jan 2, 2026 | QTRX Quanterix Corp | Award(A) | 23,372 | - | $0 | Direct |
| Aug 5, 2025 |  VIGL Vigil Neuroscience, Inc. | Disposition(D) | 222,687 | - | - | Direct |
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| Mar 3, 2025 | VIGL Vigil Neuroscience, Inc. | Award(A) Stock Option Award (Right to Buy) | 485,000 | - | - | Direct |
| Jan 2, 2025 | QTRX Quanterix Corp | Award(A) | 7,435 | - | $0 | Direct |
| Dec 19, 2024 | VIGL Vigil Neuroscience, Inc. | Purchase(P) | 5,000 | $1.68 | $8,400 | Direct |
| Dec 18, 2024 | VIGL Vigil Neuroscience, Inc. | Purchase(P) | 5,000 | $1.67 | $8,350 | Direct |
| Dec 5, 2024 | VIGL Vigil Neuroscience, Inc. | Purchase(P) | 5,000 | $2.34 | $11,700 | Direct |
| Oct 2, 2024 | QTRX Quanterix Corp | Award(A) | 12,800 | - | $0 | Direct |
1-12 of 12 transactions
About Magovcevic-Liebisch Ivana
Magovcevic-Liebisch Ivana (SEC CIK 0001279281) files insider reports with the SEC as Director of Quanterix Corp (QTRX), Director of Acrivon Therapeutics, Inc. (ACRV) and President and CEO of Vigil Neuroscience, Inc. (VIGL).
Signal8 holds 13 ownership filings by Magovcevic-Liebisch Ivana (1 Form 3, 12 Form 4), filed between Oct 3, 2024 and Oct 2, 2026. Those filings report 12 transactions, from Oct 2, 2024 to Oct 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Magovcevic-Liebisch Ivana's filings is in BILLERICA, MA.
Recent filings by Magovcevic-Liebisch Ivana
- Oct 2, 2026: Option exercise of QTRX shares (Form 4, code M).
- Jun 17, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
- May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
- Jan 2, 2026: Grant or award of QTRX shares (Form 4, code A).
- Aug 5, 2025: Disposition to issuer transaction of VIGL shares (Form 4, code D).
Other insiders filing for Quanterix Corp (QTRX)
- Miller Michael Francis, Chief Technology Officer
- Mendel Scott, Director
- DONNELLY WILLIAM P, Director
- Gute James Edward Jr., Chief Commercial Officer
- Elliott Jeffrey Thomas, Director
- Faessler Jason F., Chief Financial Officer